BA
ACHN

BlackRock Advisors’s Achillion Pharmaceuticals ACHN Stock Holding History

BlackRock Advisors’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$1.57M Buy
381,089
+76,637
+25% +$407K ﹤0.01% 1627
2016
Q3 		$2.47M Buy
304,452
+120,616
+66% +$1.03M ﹤0.01% 1385
2016
Q2 		$1.43M Buy
183,836
+79,439
+76% +$681K ﹤0.01% 1603
2016
Q1 		$806K Buy
104,397
+10,320
+11% +$75.6K ﹤0.01% 1844
2015
Q4 		$1.01M Buy
94,077
+8,707
+10% +$79.2K ﹤0.01% 1701
2015
Q3 		$590K Sell
85,370
-11,847
-12% -$96.5K ﹤0.01% 2077
2015
Q2 		$861K Buy
97,217
+28,102
+41% +$266K ﹤0.01% 1774
2015
Q1 		$681K Buy
69,115
+17,236
+33% +$215K ﹤0.01% 1838
2014
Q4 		$636K Sell
51,879
-180,709
-78% -$2.21M ﹤0.01% 1812
2014
Q3 		$2.32M Buy
232,588
+100,955
+77% +$937K ﹤0.01% 1135
2014
Q2 		$996K Sell
131,633
-272,574
-67% -$1.09M ﹤0.01% 1504
2014
Q1 		$1.33M Sell
404,207
-231,327
-36% -$810K ﹤0.01% 1360
2013
Q4 		$2.11M Sell
635,534
-65,143
-9% -$189K ﹤0.01% 1165
2013
Q3 		$2.12M Sell
700,677
-477,470
-41% -$3.27M ﹤0.01% 1149
2013
Q2 		$9.64M Buy
+1,178,147
New +$8.99M 0.01% 793

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock Advisors's ACHN Position: Q4 2016 in Review

BlackRock Advisors increased its Achillion Pharmaceuticals (ACHN) stake by 25% in Q4 2016, buying an estimated $407K and bringing the position to 381,089 shares worth $1.57M. The position accounts for ﹤0.01% of the portfolio, ranked #1627.

BlackRock Advisors first reported a position in ACHN in Q2 2013 and has held it in 15 quarters since. The position peaked at $9.64M in Q2 2013. 140 funds tracked by Wall St. Rank hold ACHN as of Q4 2016.

  • BlackRock Advisors held 381,089 shares of Achillion Pharmaceuticals worth $1.57M as of Q4 2016.
  • BlackRock Advisors bought 76,637 Achillion Pharmaceuticals shares in Q4 2016, an estimated $407K.
  • Achillion Pharmaceuticals made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #1627 holding.
  • BlackRock Advisors first reported a position in Achillion Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Advisors's Achillion Pharmaceuticals position peaked at $9.64M in Q2 2013.
  • 140 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.